Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (121-130 of 825) with videos related to

Pageof 83
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
The association between measures of progression and survival in castrate-metastatic prostate cancerHoward I Scher, Mary Warren, Glenn Heller
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1981
Surface membrane kappa and lambda light chain expression on spleen cells of neonatal and maturing normal and immune-defective CBA/NB mice: the kappa:lambda ratio is constantS Kessler, K J Kim, I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2007
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testingAndrew J Vickers, Vennus Ballen, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2011
Circulating tumor cells as biomarkers in prostate cancerDaniel C Danila, Martin Fleisher, Howard I Scher
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1983
The ontogeny and distribution of B cells in normal and mutant immune-defective CBA/N mice: two-parameter analysis of surface IgM and IgDI Scher, J A Titus, F D Finkelman
Urology|July 1, 1995
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinomaV A Miller, V Reuter, H I Scher
The Urologic Clinics of North America|May 1, 1997
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significanceW K Kelly, S Slovin, H I Scher
The Lancet. Oncology|October 3, 2009
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetYu Chen, Nicola J Clegg, Howard I Scher
Current Opinion in Pharmacology|August 5, 2008
Targeting the androgen receptor pathway in prostate cancerYu Chen, Charles L Sawyers, Howard I Scher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy dataGlenn Heller, Michael W Kattan, Howard I Scher
Pageof 83

Showing results (121-130 of 825) with videos related to

Sort By:
Pageof 83
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
The association between measures of progression and survival in castrate-metastatic prostate cancerHoward I Scher, Mary Warren, Glenn Heller
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1981
Surface membrane kappa and lambda light chain expression on spleen cells of neonatal and maturing normal and immune-defective CBA/NB mice: the kappa:lambda ratio is constantS Kessler, K J Kim, I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2007
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testingAndrew J Vickers, Vennus Ballen, Howard I Scher
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2011
Circulating tumor cells as biomarkers in prostate cancerDaniel C Danila, Martin Fleisher, Howard I Scher
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1983
The ontogeny and distribution of B cells in normal and mutant immune-defective CBA/N mice: two-parameter analysis of surface IgM and IgDI Scher, J A Titus, F D Finkelman
Urology|July 1, 1995
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinomaV A Miller, V Reuter, H I Scher
The Urologic Clinics of North America|May 1, 1997
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significanceW K Kelly, S Slovin, H I Scher
The Lancet. Oncology|October 3, 2009
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetYu Chen, Nicola J Clegg, Howard I Scher
Current Opinion in Pharmacology|August 5, 2008
Targeting the androgen receptor pathway in prostate cancerYu Chen, Charles L Sawyers, Howard I Scher
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 1, 2007
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy dataGlenn Heller, Michael W Kattan, Howard I Scher
Pageof 83